Market Overview

7 Biggest Price Target Changes For Tuesday

Share:
Related PTXP
Benzinga's Top Upgrades, Downgrades For May 22, 2017
Analyst Expects Energy Transfer's Deal To Acquire PennTex Will Close
Related BMRN
Benzinga's Top Upgrades, Downgrades For August 17, 2017
Wall Street's M&A Chatter From July 26: Biomarin, Sigma Designs, Colgate-Palmolive, Markel-State National

 

  • Barclays cut BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) price target from $125 to $105. BioMarin Pharmaceutical shares closed at $88.36 on Monday.
  • SunTrust Robinson Humphrey lowered the price target on Penntex Midstream Partners LP (NASDAQ: PTXP) from $20 to $18. Penntex Midstream Partners shares closed at $16.69 on Monday.
  • Imperial Capital lowered the price target for Palo Alto Networks Inc (NYSE: PANW) from $190 to $180. Palo Alto Networks shares closed at $136.26 on Monday.
  • Barclays cut the price target on United Therapeutics Corporation (NASDAQ: UTHR) from $115 to $100. United Therapeutics shares closed at $132.74 on Monday.
  • Baird cut the price target for Nivalis Therapeutics Inc (NASDAQ: NVLS) from $29 to $3. Nivalis Therapeutics shares closed at $6.25 on Monday.
  • Leerink Partners lowered the price target for Amicus Therapeutics, Inc. (NASDAQ: FOLD) from $17 to $15. Amicus Therapeutics shares closed at $8.32 on Monday.
  • Barclays cut the price target for Johnson & Johnson (NYSE: JNJ) from $130 to $125. Johnson & Johnson shares closed at $113.13 on Monday.

Latest Ratings for PTXP

DateFirmActionFromTo
May 2017CitigroupDowngradesBuyNeutral
May 2017BairdDowngradesOutperformNeutral
May 2017RBC CapitalDowngradesOutperformSector Perform

View More Analyst Ratings for PTXP
View the Latest Analyst Ratings

Posted-In: Price Target ChangesPrice Target Analyst Ratings

 

Related Articles (BMRN + FOLD)

View Comments and Join the Discussion!
Loading...
Loading...